Company profile for Pinteon Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We aim to protect and preserve brain function in patients suffering from tauopathies. Millions of people around the world are living with diseases such as traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP). We are inspired by the perseverance of patients and caregivers navigating the uncertainty of these devastating neurodegenerative disea...
We aim to protect and preserve brain function in patients suffering from tauopathies. Millions of people around the world are living with diseases such as traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP). We are inspired by the perseverance of patients and caregivers navigating the uncertainty of these devastating neurodegenerative diseases. Their determination to fight for a better future motivates us to aggressively pursue and target toxic tau. We are moving with focus, urgency and commitment to bring our novel therapy to these patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1188 Centre Street Newton Center, Massachusetts, 02459
Telephone
Telephone
917-607-0015
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20210617005096/en

BUSINESSWIRE
17 Jun 2021

https://www.businesswire.com/news/home/20210617005096/en

BUSINESSWIRE
16 Jun 2021

https://www.businesswire.com/news/home/20210406005121/en

BUSINESSWIRE
06 Apr 2021

https://www.businesswire.com/news/home/20210406005121/en/Pinteon-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Study-of-PNT001-in-Patients-with-Acute-Traumatic-Brain-Injury

BUSINESSWIRE
06 Apr 2021

Services

Upload your portfolio for free, ask us

Drug Product Manufacturing

Click here to discover the service providers for Drug Product Manufacturing

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty